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Microglial cells become dystrophic with aging; this phenotypic alteration contributes
to basal central nervous system (CNS) neuroinflammation being a risk factor for age
related neurodegenerative diseases. In previous studies we have observed that insulin
like growth factor 1 (IGF1) gene therapy is a feasible approach to target brain cells, and
that is effective to modify inflammatory response in vitro and to ameliorate cognitive or
motor deficits in vivo. Based on these findings, the main aim of the present study is to
investigate the effect of IGF1 gene therapy on microglia distribution and morphology in
the senile rat. We found that IGF1 therapy leads to a region-specific modification of aged
microglia population.
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INTRODUCTION
Microglia, the immune cells of the central nervous system (CNS), suffer a phenotypic alteration
during aging that is characterized by decreased motility and inefficient surveillance (Streit et al.,
2004; von Bernhardi et al., 2016; Koellhoffer et al., 2017). This dystrophic cellular phenotype
of microglia is associated with the loss of their neuroprotective function, which contributes to
increased basal CNS neuroinflammation with aging and may represent a risk factor for cognitive
and motor impairment, depression or diverse age related neurodegenerative diseases (Streit and
Xue, 2010; Cunningham, 2013; Patel et al., 2015; Pekny and Pekna, 2016; Ransohoff, 2016;
Spittau, 2017).
A feasible approach to modulate microglia function in the aged brain is the use of neurotrophic
factors that polarize these cells into a more neurotrophic/neuroprotective phenotype. Among
these is insulin like growth factor 1 (IGF1; Arevalo et al., 2010; Suh et al., 2013; Acaz-Fonseca
et al., 2014; Labandeira-Garcia et al., 2017), which exerts neuroprotective actions in the CNS
(Piriz et al., 2011; Torres Aleman, 2012; Morel et al., 2016), including the aged brain (Piriz et al.,
2011; Deak and Sonntag, 2012; Labandeira-Garcia et al., 2017). Previous studies have shown
the viability of IGF1 gene therapy to target brain cells in vivo (Hereñú et al., 2009) and to
Abbreviations: IGF1, insulin like growth factor 1; RAd, recombinant adenovirus; DsRed, Discosoma Red fluorescent
protein; CNS, central nervous system.
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decrease behavioral functional impairments in aged rats (Nishida
et al., 2011; Pardo et al., 2016). In the present study we report that
IGF1 therapy lead to a region-specific modification in microglia
number and morphology in the aged brain.
MATERIALS AND METHODS
Adenoviral Vectors
We employed recombinant adenoviral vectors (RAd) previously
constructed in our laboratory (Hereñú et al., 2007) as carriers
to deliver either the therapeutic cDNA of IGF1 gene (RAd-
IGF1) or the red fluorescent protein from Discosoma sp
DsRed (RAd-DsRed).
Animals and Experimental Procedures
Female senile Sprague-Dawley rats (28 months old) were used.
These rats have a maximum life expectancy of 36 months
(Mansilla et al., 2016). Animals were housed in a temperature-
controlled room (22 ± 2◦C) on a 12:12 h light/dark cycle
and fed ad libitum, with a standard chow diet containing
12.08 kJ/g calories: 69.5% from carbohydrates, 5.6% from
fat, and 24.9% from protein (Association de Cooperativas
Argentinas-S.E.N.A.S.A. No. 04-288/A). All experiments with
animals were performed according to the Animal Welfare
Guidelines of NIH (INIBIOLP’s Animal Welfare Assurance No
A5647-01). The ethical acceptability of the animal protocols
used here has been approved by our institutional IACUC
(Protocol #T09-01-2013).
On day 0 (D0), rats were anesthetized with ketamine
hydrochloride (40 mg/kg; i.p.) plus xylazine (8 mg/kg; i.m.) and
placed in a stereotaxic apparatus. Rats were randomly divided
into two groups (n = 10 per group): DsRed group, which
received an injection of RAd-DsRed; and IGF1 group, which
received an injection of RAd-IGF1. Bilateral injections in the
lateral ventricles were performed placing the tip of a 26 G needle
fitted to a 10 µL syringe at the following coordinates relative to
the Bregma: −0.8 mm anteroposterior, −4.2 mm dorsoventral
and ±1.5 mm mediolateral (Paxinos and Watson, 2007). Rats
were injected bilaterally with 8 µL per side of a suspension
containing 1010 plaque forming units (pfu) of the appropriate
vector. Body weight was determined every 2 or 3 days from
day −5 before surgery to experimental day 18. Animals were
sacrificed at experimental day 18.
Immunohistochemistry
Animals were placed under deep anesthesia and perfused with
phosphate buffered paraformaldehyde 4%, (pH 7.4) fixative. The
brains were removed and stored in paraformaldehyde 4%, (pH
7.4) overnight at 4◦C. Brains were kept in cryoprotective solution
at −20◦C until use. For immunohistochemical assessment,
brains were cut coronally in 40 µm-thick sections with a
Vibratome (Leica).
All immunohistochemical techniques were performed on
free-floating sections under moderate shaking. Washes and
incubations were done in 0.1 M phosphate buffer pH 7.4,
containing 0.3% triton X-100 (washing buffer). The endogenous
peroxidase activity was quenched for 15 min at room
temperature in a solution of 3% hydrogen peroxide in 50%
methanol. After several washes in buffer, sections were incubated
overnight at 4◦C with an Iba1 rabbit polyclonal antibody diluted
1:1,000 (WAKO CTG2683), marker of microglia/macrophages.
Sections were then washed in buffer and incubated for 2 h at
room temperature with an anti-rabbit biotinylated secondary
antibody (1:1,000, BA-1000; Vector Labs). After several washes in
buffer, sections were incubated for 90 min at room temperature
with avidin-biotin-peroxidase complex (diluted 1:500, PK-6100;
Vector ABC Elite Kit). The reaction product was revealed
by incubating the sections with 3,3-diaminobenzidine (Sigma-
Aldrich) and 0.01% hydrogen peroxide in 0.1 M phosphate
buffer. Then, sections were dehydrated, mounted on gelatinized
slides with mounting medium (Vectamount, Vector) and used
for image analysis.
Morphometric Analysis
From each rat, 1 in every 12 brain serial sections was selected. For
stereological analysis, we used an Olympus BX-51 microscope
attached to an Olympus DP70 CCD video camera (Tokyo,
Japan). All morphological parameters were assessed bilaterally.
The density of microglia in the striatum (caudate-putamen),
dorsal tier of substantia nigra pars compacta (SNCD), motor
cortex, dorsolateral entorhinal cortex (DLEnt) and perirhinal
cortex (PRh) was assessed. Areas of interest were defined in
accordance with the rat brain atlas of Paxinos and Watson
(2007). All Iba1-immunoreactive cells were manually quantified,
according to the optical disector method, using a counting frame
of 83 × 83 µm at 600× magnification. A total of 40–85 counting
frames were analyzed. Cells in the uppermost focal plane and/or
intersecting the exclusion boundaries of the counting frame were
not counted. Cells counts are expressed as number/mm3.
Iba1-immunoreactive cells were classified as: (1) non-
reactive/ramified microglia; cells with small cell body and few
large to no branches; and (2) reactive/ameboid microglia; cells
with large or ameboid cell bodies, numerous retracted processes
and intense Iba1 immunostaining (Acaz-Fonseca et al., 2015).
The proportion of reactive vs. total microglia was determined for
each brain region analyzed.
Statistical Analysis
Data shown in the figures are presented as the mean ± standard
error of the mean (SEM). The size of the experimental groups
is indicated in each figure legend. Gaussian distribution of
data sets was assessed by Kolmogorov-Smirnov test. Statistical
analysis was performed by using the software GraphPad Prism
6 (GraphPad Software). To determine significant differences in
microglia densities and reactivity between groups, we used t-test
analysis. P-values < 0.05 were considered to be significant.
RESULTS
Body Weight Gain
Animal weight was recorded every 2 or 3 days. At day two
after administration of RAd-DsRed or RAd-IGF1, both groups
experienced a transient loss of body weight due to the surgical
procedure. Subsequently, both groups of rats recovered the initial
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FIGURE 1 | Representative images of motor cortex (A,B), striatum (C,D), substantia nigra compact part dorsal (E,F) and dorsolateral entorhinal and perirhinal
cortex (G,H) of the recombinant adenovirus (RAd)-discosoma Red fluorescent protein (DsRed; A,C,E,G) and RAd-Insulin like growth factor 1 (IGF1; B,D,F,H) groups
at a magnification of 40X (scale bars: 500 microns), with insets at a magnification of 600X (scale bars: 50 microns). Panels (I; MC, motor cortex; Cpu,
Striatum/caudate-putamen) and (K; PRh, perirhinal cortex; DLEnt, dorsolateral entorhinal cortex; and SNCD, substantia nigra compact part dorsal) show a
representation of the coronal brain sections where the analyzed regions; are highlighted. Panels (J,L) show microglia densities in the different groups in the analyzed
regions. Data are given as means ± SEM (N = 5/group). ∗Significant differences (p < 0.05).
weight and remained stable until the end of the experiment
(Supplementary Figure S1).
Gene Therapy Affects the Number and
Reactivity of Microglia
Iba-1 immunoreactive cells were analyzed in the motor cortex,
striatum, substantia nigra, DLEnt and PRh. As shown in Figure 1,
significant differences in the number of Iba-1 immunoreactive
cells were detected in the striatum between the animals injected
with RAd-DsRed and the animals injected with RAd-IGF1.
Thus, there was a higher number of Iba-1 immunoreactive cells
in the animals injected with RAd-IGF1 than in the animals
injected with RAd-DsRed (Figure 1). No significant differences
were detected in the number of Iba-1 immunoreactive cells
in the motor cortex, substantia nigra and the PRh of the
animals injected with RAd-IGF1 and the animals injected with
RAd-DsRed (Figure 1).
In addition to the differences in total number, obvious
qualitative differences were observed in the morphology of
Iba-1 immunoreactive cells between the different experimental
groups; with more cells with a reactive phenotype in the
striatum of animals injected with Rad-IGF1 (Figure 2). Indeed,
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FIGURE 2 | Proportion of reactive microglia with ameboid morphology and enlarged cell body in RAd-DsRed and RAd-IGF1 groups in the different brain regions
analyzed. Statistical results indicate significant differences between the experimental groups within the same brain region. Data are given as means ± SEM
(N = 5/group). ∗Significant differences (p < 0.05).
the quantitative analysis of reactive/ameboid cells and non-
reactive/ramified cells showed a significant increase in the
proportion of reactive cells in the striatum of the animals
injected with RAd-IGF1 in comparison with the striatum of
RAd-DsRed injected rats. In contrast, no significant differences
in the proportion of reactive and non-reactive phenotypes were
detected in the other brain regions analyzed (Figure 2).
In summary, these findings indicate that the injection
of RAd-IGF1 is able to increase the number of Iba-1
immunoreactive cells and the proportion of Iba-1
immunoreactive cells with a reactive phenotype in a specific
brain region.
DISCUSSION
We previously demonstrated that ICV IGF1 gene therapy
is effective to transduce brain ependymal cells with high
efficiency, achieving effective release of transgenic IGF1 into
the cerebrospinal fluid (CSF; Hereñú et al., 2009) and restoring
motor performance in aged animals (Nishida et al., 2011). Thus,
we decided to use the ependymal route to implement IGF1 gene
therapy in aging rats with the goal to characterize microglia
number and distribution in different brain regions related with
cognition or motor performance.
ICV gene therapy caused a significant but transient
decrease in weight gain in both DsRed and IGF1 groups.
Body weigh may be affected by surgery and also by a
temporary induction of endogenous neurotrophic factors,
such as GDNF, which has been reported to cause body weight
loss (Morel et al., 2010). This effect could be greater in
the IGF1 group, since IGF1 may regulate the hypothalamic
system controlling body weight and energy expenditure
(Werner and LeRoith, 2014).
We expected that IGF1 gene therapy will decrease microglia
reactivity, since this therapy has been shown to reduce the
reactivity of astrocytes in response to proinflammatory stimuli
in vitro (Bellini et al., 2011). And to exert neuroprotective and
neuroreparative actions in experimental animal models of stroke
(Zhu et al., 2008; Liu et al., 2017). However, other studies have
reported detrimental actions of IGF1 receptor signaling in the
brain of mouse models of Alzheimer’s disease (Cohen et al.,
2009; Freude et al., 2009; Gontier et al., 2015). In this study we
found is that IGF1 gene therapy increased the number and the
proportion of microglia with a reactive phenotype in a region
dependent manner.
We have not a definitive explanation for the regional effect
of RAd-IGF1 on striatal microglia. It is well established that
microglia (Breese et al., 1996; Walter et al., 1999; Chesik et al.,
2004; Suh et al., 2013; Rodriguez-Perez et al., 2016; Trueba-Saiz
et al., 2017) and other cell types in the brain (Fernandez and
Torres-Alemán, 2012) express IGF1 receptors. It is possible that
regional differences in the expression of these receptors may
cause a different sensitivity to IGF1 released and delivered to the
ventricles by infected ependymal cells.
The functional consequences of these changes inmicroglia are
unknown. However, it has been described that treatments that
leads to the depletion of microglia in injury models increases
neuronal death (Vinet et al., 2012). Reciprocally, repletion of
microglia or introduction of exogenous microglia result in
neuronal rescue, driven possibly by microglial production of
trophic growth factors, or via the clearance of deleterious
byproducts of metabolism and neurotransmission (Streit et al.,
2004; Nissen, 2017). Therefore, it is possible that the increased
number of microglia cells induced by IGF1 gene therapy
may exert a protective function in the striatum of older rats.
Indeed, previous studies have shown that the administration of
RAd-IGF1 in the brain, following the protocol used in the present
study, results in an improvement in motor function of senile rats
(Nishida et al., 2011).
In summary, our findings indicate that ICV IGF1 gene
therapy specifically modifies the number and phenotype of
microglia in the striatum of senile rats, suggesting that such
a therapy may be useful to alter the function of dystrophic
microglia, at least in specific brain regions. Further studies should
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determine whether the effect of IGF1 gene therapy on microglia
is age-dependent and is also detected in male animals.
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